LuminoDx is pleased to announce that they will be presenting the most recent data generated with HepatoTrack, the CLIA certified liquid biopsy liver transplant rejection predictive test. LuminoDx will also be exhibiting at the conference.
https://mma.prnewswire.com/media/2741594/HEPATOTRACK_PHOTO.jpg
LuminoDx has shown that HepatoTrack results have a stronger correlation to acute cellular rejection (ACR) status than liver tests like aspartate transaminase (AST) and alanine transaminase (ALT), and is simpler, faster, and more cost effective compared to tissue biopsy.
HepatoTrack will allow physicians who are monitoring / lowering immunosuppressive therapy post liver transplant, to quickly and safety determine the livers health status in real time explained Yipeng Wang, co-founder and CEO of LuminoDx.
LuminoDx's scientific founders, Gordon Vansant and Yipeng Wang, bring extensive technical and scientific expertise in assay development with a focus on liquid biopsy. This includes developing molecular and proteomic assays and testing samples from both non-clinical and clinical studies to support therapeutic drug development. “Now, with the CLIA certified HepatoTrack test, we are equipped to support transplant physicians and hepatologists with critical results to support safe immunosuppression attenuation,” said Gordon Vansant, CBO and co-founder of LuminoDx.
About LuminoDx:
LuminoDx is a San Diego-based diagnostic company specializing in liquid biopsy and molecular testing. With over 80 years of combined expertise in diagnostic development, we are committed to providing innovative solutions for both clinical and research applications. Our flagship offering is a liquid biopsy solution for post-liver transplant management and care. By leveraging proprietary biomarkers, we enable precision monitoring of allograft health, optimize immunosuppression dosing, and reduce the risk of comorbidities. Additionally, we provide services with Olink proteomics analysis, ELISA analysis, spatial biology with ELEMENT's Aviti24 system, and Laboratory Test Development.
For more information visit: www.luminodx.com
https://mma.prnewswire.com/media/2578884/LuminoDx_Logo.jpg
https://c212.net/c/img/favicon.png?sn=LA41477&sd=2025-07-31
View original content to download multimedia:https://www.prnewswire.com/news-releases/luminodx-will-be-presenting-and-exhibiting-at-the-world-transplant-congress-in-san-francisco-302518371.html
SOURCE LuminoDx
https://rt.newswire.ca/rt.gif?NewsItemId=LA41477&Transmission_Id=202507310800PR_NEWS_USPR_____LA41477&DateId=20250731